While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a full-blown stock-market meltdown.
Even the launch of generic versions of heart failure blockbuster Entresto and Trump's threats to cut drug prices won't overshadow the strong performance of Novartis AG's oncology franchise. So, sales of Scemblix, which is rapidly capturing the chronic myeloid leukemia market, reached $298 million for NVS in the second quarter of 2025, an increase of 81.7% year-on-year. Also, I was pleased to se...
Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring 1 1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines 2,3 Remibrutinib al...
The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday.
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring 1 1.7 million people in US live with CSU; more than half remain symptomatic despite increasin...
Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx® (secukinumab) the option to purchase it at a 55% discount off the list price. Cosentyx, Novartis top selling product in the US, is a biologic that is FDA-approved for the treatment o...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.